Elevation Oncology, Inc. Common stock
N/A
USD
N/A
N/A
...
Chart
Financials
Description
ELEV Company Description
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
ELEV Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view ELEV Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of ELEV by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ELEV's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
WallStreetBets
Number of mentions of ELEV in WallStreetBets Daily Discussion
ELEV News
Recent insights relating to ELEV
CNBC Recommendations
Recent picks made for ELEV stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in ELEV
Corporate Flights
Flights by private jets registered to ELEV
Our Analysis